CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

Laurence Balanco, the CLSA chartist, expects the Nifty 50 index to slip to levels of 22,000, as it has broken below key support levels on Monday. In a note, Balanco said that the lack of follow ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...

2025 Market Outlook: CLSA anticipates a challenging year for the Nifty in 2025, driven by an uncertain and risky global macro environment coupled with a near-term economic slowdown in India.

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has included Zomato in its High Conviction Outperform list, maintaining an "Overweight" rating and increasing the target ...

HCLTech declared a dividend of Rs 18 per share, including a special Rs 6 per share dividend to commemorate 25 years since its ...

CLSA believes the company must reduce its dependence on the Creta and introduce higher-priced SUVs in the Rs 20 Lakh+ segment ...